Erin Hassett, ANP-BC

Dr. Cynthia Tsay is an Assistant Professor of Medicine at Weill Cornell Medicine and New York-Presbyterian Hospital and a general gastroenterologist with a clinical and research interest in early gastric cancer, gastric intestinal metaplasia, and other conditions involving the stomach. She is interested in the application of machine learning and artificial intelligence in the risk stratification and early detection of premalignant lesions in high risk populations, as well as the role of the microbiome in these conditions and ways in which medications alter the gastrointestinal microbiome. She has published in Gastroenterology, Clinical Gastroenterology and Hepatology, Alimentary Pharmacology & Therapeutics and the American Journal of Gastroenterology. She obtained her B.A. in the History of Science and the History of Medicine at Yale College and her M. Phil in the History, Philosophy, and Sociology of Science, Medicine, and Technology at the University of Cambridge. Dr. Tsay returned to New Haven where she earned her M.D. at the Yale School of Medicine and completed her residency in Internal Medicine at Yale New Haven Hospital. She also has a M.P.H in Epidemiology from the Harvard T.H. Chan School of Public Health. She completed her fellowship training in Gastroenterology and Hepatology at the Johns Hopkins Hospital where she served as chief fellow during her last two years. Dr. Tsay is also passionate about medical education and the experience of trainees, having served as president of the Yale Resident and Fellow Senate and the chair of the Johns Hopkins Clinical Fellows Council.

Babak Navi, MD, MSBabak Navi, M.D., M.S. received his medical degree from New York University, where he graduated with honors. He completed a residency in neurology at Weill Cornell Medical Center and served as the Chief Resident in his final year. He completed a fellowship in vascular neurology at the University of California, San Francisco, where he also became certified in comprehensive neurosonology. In 2011, Dr. Navi joined the neurology faculty at Weill Cornell Medical College. Here, he received a Masters of Science in Research from the Cornell Graduate School of Medical Sciences. Dr. Navi is currently an Associate Professor of Neurology and Neuroscience, the Vice Chair for Neurology Hospital Services, and the Division Chief of Stroke and Hospital Neurology. He also serves as the Medical Director of the Weill Cornell Stroke Center and Acting Director of the NewYork-Presbyterian Hospital Mobile Stroke Unit Program.Dr. Navi is an expert on the relationship between cancer and stroke. He has published numerous studies on this topic and led the first randomized trial to compare different blood thinning strategies for patients with cancer and stroke. Dr. Navi has also conducted research studies on stroke of undetermined cause, stroke during pregnancy and other prothrombotic states, the safety and efficacy of mobile stroke units, and physicians’ ability to prognosticate in severe brain injury. His work has been published in leading medical journals, including the NEJM, JAMA, JACC, Neurology, Annals of Neurology, JAMA Neurology, Stroke, and Critical Care Medicine. Dr. Navi has been awarded several research grants during his career, including from the NIH, PCORI, and foundations. He has considerable experience in conducting clinical trials and served as the Cornell Site Principal Investigator for the landmark POINT and BEST-MSU trials. Dr. Navi is an Associate Editor for the journal Neurohospitalist and an editorial board member for JAMA Neurology. He received the Young Heart Award by the American Heart Association New York Chapter in 2017. Select Publications1. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926-938. 2. Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MSV, Panageas KS, DeAngelis LM. Association between incident cancer and subsequent stroke. Ann Neurol. 2015;77:291-300. 3. Navi BB, Marshall RS, Bobrow D, Singer S, Stone JB, DeSancho MT, DeAngelis LM. Enoxaparin vs. aspirin in patients with cancer and ischemic stroke: the TEACH pilot randomized clinical trial. JAMA Neurol. 2018;75:379-381. 4. Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MSV. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med. 2014;370:1307-1315.5. Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, Iadecola C, Elkind MS, DeAngelis LM. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology. 2014;83:26-33.

Dr. Bashir Al Hussein is a Urologic Oncologist and Assistant Professor of Urology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. He completed his urology residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a Society of Urologic Oncology (SUO) fellowship at Vanderbilt University Medical Center. He also holds a Master of Public Health in Epidemiology from Vanderbilt University and earned his medical degree from the University of Jordan in Amman.Dr. Al Hussein is a urologic cancer surgeon who specializes in the diagnosis and management of genitourinary malignancies, including prostate, kidney, bladder, testicular, and penile cancers. He provides comprehensive cancer care using both robotic and open surgical approaches, tailored to the complexity and stage of each patient’s disease. His expertise includes minimally invasive robotic procedures—such as radical prostatectomy, partial nephrectomy, and cystectomy—as well as complex open operations for advanced or anatomically challenging tumors.Dr. Al Hussein’s research focuses on applying epidemiologic methods to improve the quality of cancer care, with an emphasis on decision-making, survivorship, and health literacy. His work has been published in leading journals, including The Journal of the American Medical Association (JAMA), The New England Journal of Medicine, and JAMA Internal Medicine. He is a recipient of the American Urological Association Research Scholar Award and serves as Director of the Adult Urology Clinic within the Department of Urology at Weill Cornell Medicine.NewsMost Men With Low-Risk Prostate Cancers Now Forgo Immediate Surgeryhttps://www.usnews.com/news/health-news/articles/2023-04-04/most-men-with-low-risk-prostate-cancers-now-forgo-immediate-surgeryDecade-Long Study Offers Guidance on Treatments for Prostate Cancerhttps://www.usnews.com/news/health-news/articles/2024-01-24/decade-long-study-offers-guidance-on-treatments-for-prostate-cancerInsights into adverse effects may help guide prostate cancer treatment decision-makinghttps://www.healio.com/news/hematology-oncology/20240227/insights-into-adverse-effects-may-help-guide-prostate-cancer-treatment-decisionmakingComparing Side Effects of Prostate Cancer Treatmentshttps://newsinhealth.nih.gov/2024/04/comparing-side-effects-prostate-cancer-treatmentsMore U.S. Prostate Cancer Patients Choosing Active Surveillancehttps://www.newswise.com/articles/more-u-s-prostate-cancer-patients-choosing-active-surveillance2More Men Choose Active Surveillance for Prostate Cancerhttps://www.newsmax.com/health/health-news/prostate-cancer-low-risk/2023/04/05/id/1115105/More men with prostate cancer opting for active surveillancehttps://www.healio.com/news/hematology-oncology/20230403/more-men-with-prostate-cancer-opting-for-active-surveillancehttps://www.usatoday.com/story/news/health/2024/01/24/prostate-cancer-treatment-study/72336323007/10-year study evaluates prostate cancer treatments, side effectshttps://www.msn.com/en-us/health/other/10-year-study-evaluates-prostate-cancer-treatments-side-effects/ar-BB1hc5v7Understanding Functional Outcomes in Prostate Cancerhttps://www.medscape.com/s/viewarticle/understanding-functional-outcomes-prostate-cancer-2024a10001t2?src=rssTreatment Adverse Events Vary With Favorable, Unfavorable Prognosis in Prostate Cancerhttps://www.physiciansweekly.com/treatment-adverse-events-vary-with-favorable-unfavorable-prognosis-in-prostate-cancer/Cory Booker didn’t go to the bathroom for 25 hours. Is that … OK?https://www.theguardian.com/wellness/2025/apr/03/how-long-without-peeing-is-bad